Lilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first time
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Eli Lilly’s powerful weight-loss drug Zepbound hit 77,590 new prescriptions in the U.S. for the week ending March 8, surpassing Novo Nordisk’s rival obesity medicine Wegovy for the first time since it was launched, according to data from IQVIA.
:max_bytes(150000):strip_icc():format(jpeg)/FPM-Best-Personal-Loans-Methodology-Recirc-468fcab5bfa84ae485bd56843cf5c0eb.png "How We Review and Rate Personal Loan Lenders")
:max_bytes(150000):strip_icc():format(jpeg)/PropertyValuation-4ecdfe3a87144fe998087ef433f49c13.jpeg "Is There a Gender Gap in Home Equity Loans?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1346781100-2724c28da6b2479b88db9d1337ebe926.jpg "Buy Now, Pay Later or Rent-to-Own: Which Is the Smarter Way to Pay for Purchases?")